Exact sciences corporation
EXAS 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
EXAS 近期報酬表現
0.41%
Exact sciences corporation
-0.98%
同產業平均
-0.22%
S&P500
與 EXAS 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
VCYT | Veracyte inc | 3 分 | 1 分 | 2 分 | 2 分 | 1 分 | |
TXG | 10x genomics inc | 2 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
ADPT | Adaptive biotechnologies corp | 4 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
PACB | Pacific biosciences of california inc | 3 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
TWST | Twist bioscience corp | 3 分 | 3 分 | 2 分 | 2 分 | 1 分 |
- VCYT Veracyte inc價值 3 分趨勢 1 分波段 2 分籌碼 2 分股利 1 分查看更多
EXAS 公司資訊
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company's products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company's flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient's breast tumor tissue.